Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Subdermal implants, changed once or twice per year, could deliver GLP-1R agonist with no need for a weekly injection.

Daniel Drucker, the Canadian scientist renowned for discoveries that sparked the advent of Ozempic and other GLP-1 medicines ...

Vapourtec’s R-Series flow chemistry system, equipped with a UV-150 photochemical reactor, has been cited in research by scientists* at Novo Nordisk in the C-terminal a-amination of peptides and ...